Abstract
Osteoarthritis (OA) is an age-related joint disease with a strong and complex genetic component. Genome-wide association studies (GWAS) discovered a large number of genomic regions associated with OA. Nevertheless, to link associated genetic variants affecting the expression of OA-risk genes in relevant tissues remains a challenge. Here, we showed an unbiased approach to identify transcript single nucleotide polymorphisms (SNPs) of OA risk loci by allelic expression imbalance (AEI). We used RNA sequencing of articular cartilage (N = 65) and subchondral bone (N= 24) from OA patients. AEI was determined for all genes present in the 100 regions reported by GWAS catalog. The count fraction of the alternative allele (φ) was calculated for each heterozygous individual with the risk-SNP or with the SNP in linkage disequilibrium (LD) with it. Furthermore, a meta-analysis was performed to generate a meta-φ (null hypothesis median φ=0.49) and P-value for each SNP. We identified 30 transcript SNPs subject to AEI (28 in cartilage and 2 in subchondral bone). Notably, 10 transcript SNPs were located in genes not previously reported in the GWAS catalogue, including two long intergenic non-coding RNAs (lincRNAs), MALAT1 (meta-φ=0.54, FDR=1.7×10−4) and ILF3-DT (meta-φ=0.6, FDR=1.75×10-5). Moreover, 14 drugs were interacting with 7 genes displaying AEI, of which 7 drugs has been already approved. By prioritizing proxy transcript SNPs that mark AEI in cartilage and/or subchondral bone at loci harboring GWAS signals, we present an unbiased approach to identify the most likely functional OA risk-SNP and gene. We identified 10 new potential OA risk genes ready for further, translation towards underlying biological mechanisms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funding by: TreatOA which is funded by the European Commission framework 7 programme grant 200800. BBMRI Metabolomics Consortium funded by BBMRI-NL, a research infrastructure financed by the Dutch government (NWO, grant nr 184.021.007 and 184033111). Dutch Scientific Research council NWO /ZonMW VICI scheme (91816631/528).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the Research Arthritis and Articular Cartilage (RAAK) study was obtained from the medical ethics committee of the Leiden University Medical Center (P08.239/P19.013), and informed consent was obtained from all patients included.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). All other data relevant to the study are included in the article.
Abbreviations
- OA
- Osteoarthritis
- GWAS
- Genome-wide association study
- AEI
- Allelic expression imbalance
- LD
- Linkage disequilibrium
- COLGAT2
- Collagen Beta(1-O)Galactosyltransferase 2
- MGP
- Matrix Gla Protein
- SNPs
- Single nucleotide polymorphisms
- LincRNA
- Long intergenic non-coding RNAs
- MALAT1:
- Metastasis Associated Lung Adenocarcinoma Transcript 1
- FDR
- False Discovery Rate
- ILF3-DT
- Interleukin Enhancer Binding Factor 3 Divergent Transcript
- HLA
- Human Leukocyte Antigen
- HLA-DPA1:
- Human Leukocyte Antigen-heterodimer consisting of an alpha
- HLA-DPB1:
- Human Leukocyte Antigen-heterodimer consisting of an alpha
- TNC:
- Tenascin C
- FC
- Fold Change
- SLC44A2:
- Solute Carrier Family 44 Member 2
- DGBI
- Drug Gene Interaction Database
- IG
- Interaction group
- CRISPR-cas9
- Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9
- WWP2
- WW Domain Containing E3 Ubiquitin Protein Ligase 2
- mQTL
- methylation Quantitative Trait Loci
- SERPINA2
- Serpin Family A Member 2
- ALDH1A2:
- Aldehyde Dehydrogenase 1 Family Member A2
- RBP4
- Retinol binding protein 4
- MMP-3
- matrix metalloproteinase-3
- MMP-13
- matrix metalloproteinase-13
- NF-κB1
- Nuclear Factor kappa B1
- IL-6
- Interleukin-6
- miR-9
- microRNA-9
